Early Local Tumour Control and Feasibility of Intratumoral P-32 Microparticle Implantation in Patients with Locally Advanced Pancreatic Cancer: A Prospective Single-Center Observational Cohort Study
4 affiliations
- 1Endoscopy Unit, Gastroenterology Department, Hospital Universitario Río Hortega, 47012 Valladolid, Spain
- 2Medical School of Athens, National and Kapodistrian University of Athens, 11527 Athens, Greece
- 3Gastroenterology Department, Agios Savvas Hospital, 11522 Athens, Greece
- 4First Propaedeutic Department of Surgery, School of Medicine, National and Kapodistrian University of Athens, Hippocration General Hospital of Athens, 11527 Athens, Greece
Abstract
Background: Evidence regarding EUS-guided intratumoral phosphorus-32 (P-32) microparticle implantation for locally advanced pancreatic cancer (LAPC) remains limited. This prospective pilot study evaluated its technical feasibility, preliminary safety, and early disease-control outcomes when administered in combination with gemcitabine plus nab-paclitaxel. Methods: Seventeen patients with unresectable LAPC underwent EUS-guided intratumoral P-32 microparticle implantation through a 22-gauge fine-needle aspiration needle during the fourth week of systemic chemotherapy. Intratumoral distribution was assessed using Bremsstrahlung SPECT/CT. Tumour response was evaluated according to RECIST version 1.1, and treatment-emergent adverse events were graded according to CTCAE version 4.0. The main secondary endpoint was local disease control rate at approximately 16 weeks (LDCR16w). All analyses were descriptive. Results: Implantation was technically successful in all 17 patients (100.0%; exact 95% CI, 80.5–100.0%), and SPECT/CT confirmed intratumoral distribution in every case. No implantation-related procedural complications were recorded (0/17; exact 95% CI, 0.0–19.5%). At approximately 16 weeks, CT assessment was available for 16 patients: seven had a partial response and nine had stable disease. The LDCR16w was 16/16 among evaluable patients (100.0%; exact 95% CI, 79.4–100.0%) and 16/17 in the all-treated analysis (94.1%; exact 95% CI, 71.3–99.9%). A reduction in CA19-9 of at least 50% was observed in 13/16 evaluable patients. Four patients underwent subsequent R0 resection (4/17, 23.5%; exact 95% CI, 6.8–49.9%). Adverse events were predominantly grade 1–2; one grade 3 abdominal pain event and no grade 4–5 events were recorded. Only three deaths occurred during a median OS follow-up of 15.6 months, making survival estimates exploratory and statistically immature. Conclusions: In this small, single-center pilot cohort of highly selected patients, EUS-guided intratumoral P-32 microparticle implantation combined with gemcitabine plus nab-paclitaxel was technically feasible and provided preliminary safety information. Because of the absence of a chemotherapy-only comparator, the small sample size, and the limited follow-up, the radiographic, biomarker, resection, and survival outcomes cannot be attributed specifically to P-32 implantation and should be considered descriptive and hypothesis-generating. Larger controlled studies with longer follow-up are required to determine clinical efficacy.
Related
- Longitudinal Changes in Anxiety and Depression Following First Implantable Cardioverter-Defibrillator Implantation: A Prospective Observational Study
- Ultrasound-guided peripheral regional anesthesia vs local infiltration anesthesia for cardiac device implantation: A propensity score–matched prospective observational cohort study
- Persistent pocket-site pain after cardiac implantable electronic device implantation: a prospective observational study of prevalence, neuropathic characteristics, and quality of life.
- Twelve-month outcomes after fixation-free, 3-dimensional, lightweight SWING-Mesh implantation for minimally-invasive inguinal hernia repair: a multicenter prospective observational study
- Home cardiotocography for high-risk obstetric care: A prospective observational feasibility study
BibTeX
@article{kontos2026early,
title = {{Early Local Tumour Control and Feasibility of Intratumoral P-32 Microparticle Implantation in Patients with Locally Advanced Pancreatic Cancer: A Prospective Single-Center Observational Cohort Study}},
author = {Athanasios Kontos and Ioannis Riris and Dimitrios Kypraios and Nikolaos Alexakis and Georgios Zografos and Konstantinos Toutouzas},
journal = {Cancers},
year = {2026},
month = oct,
doi = {10.3390/cancers18203331},
url = {https://www.mdpi.com/2072-6694/18/20/3331},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Early Local Tumour Control and Feasibility of Intratumoral P-32 Microparticle Implantation in Patients with Locally Advanced Pancreatic Cancer: A Prospective Single-Center Observational Cohort Study
AU - Athanasios Kontos
AU - Ioannis Riris
AU - Dimitrios Kypraios
AU - Nikolaos Alexakis
AU - Georgios Zografos
AU - Konstantinos Toutouzas
PY - 2026
DA - 2026/10/01
JO - Cancers
DO - 10.3390/cancers18203331
UR - https://www.mdpi.com/2072-6694/18/20/3331
AB - Background: Evidence regarding EUS-guided intratumoral phosphorus-32 (P-32) microparticle implantation for locally advanced pancreatic cancer (LAPC) remains limited. This prospective pilot study evaluated its technical feasibility, preliminary safety, and early disease-control outcomes when administered in combination with gemcitabine plus nab-paclitaxel. Methods: Seventeen patients with unresectable LAPC underwent EUS-guided intratumoral P-32 microparticle implantation through a 22-gauge fine-needle aspiration needle during the fourth week of systemic chemotherapy. Intratumoral distribution was assessed using Bremsstrahlung SPECT/CT. Tumour response was evaluated according to RECIST version 1.1, and treatment-emergent adverse events were graded according to CTCAE version 4.0. The main secondary endpoint was local disease control rate at approximately 16 weeks (LDCR16w). All analyses were descriptive. Results: Implantation was technically successful in all 17 patients (100.0%; exact 95% CI, 80.5–100.0%), and SPECT/CT confirmed intratumoral distribution in every case. No implantation-related procedural complications were recorded (0/17; exact 95% CI, 0.0–19.5%). At approximately 16 weeks, CT assessment was available for 16 patients: seven had a partial response and nine had stable disease. The LDCR16w was 16/16 among evaluable patients (100.0%; exact 95% CI, 79.4–100.0%) and 16/17 in the all-treated analysis (94.1%; exact 95% CI, 71.3–99.9%). A reduction in CA19-9 of at least 50% was observed in 13/16 evaluable patients. Four patients underwent subsequent R0 resection (4/17, 23.5%; exact 95% CI, 6.8–49.9%). Adverse events were predominantly grade 1–2; one grade 3 abdominal pain event and no grade 4–5 events were recorded. Only three deaths occurred during a median OS follow-up of 15.6 months, making survival estimates exploratory and statistically immature. Conclusions: In this small, single-center pilot cohort of highly selected patients, EUS-guided intratumoral P-32 microparticle implantation combined with gemcitabine plus nab-paclitaxel was technically feasible and provided preliminary safety information. Because of the absence of a chemotherapy-only comparator, the small sample size, and the limited follow-up, the radiographic, biomarker, resection, and survival outcomes cannot be attributed specifically to P-32 implantation and should be considered descriptive and hypothesis-generating. Larger controlled studies with longer follow-up are required to determine clinical efficacy.
SN - 2072-6694
ER -